Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • NPPA fixes retail...

    NPPA fixes retail price of 21 drugs including BP, diabetes, painkillers; Details

    Meghna A SinghaniaWritten by Meghna A Singhania Published On 2019-03-01T18:13:58+05:30  |  Updated On 1 March 2019 6:13 PM IST
    NPPA fixes retail price of 21 drugs including BP, diabetes, painkillers; Details

    The NPPA order is likely to affect drug majors including Lupin, Emcure, Cipla, Mylan, Zydus, Macleods Pharmaceuticals.


    New Delhi: Through a recent notification, the government regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) has fixed the retail price of 21 drug formulations. These formulations include diabetes drug, blood pressure drug, painkillers, emergency contraceptive for women.


    The NPPA order is likely to affect drug majors including Lupin, Emcure, Cipla, Mylan, Zydus, Macleods Pharmaceuticals.


    Some of the formulations whose price has been fixed by the NPPA are Metformin + Gliclazide Tablet manufactured by the Mumbai based Lupin. The formulation is used to treat type-2 diabetes, while the formulation Cilnidipine + Telmisartan + Chlorthalidone Tablet, manufactured by Emcure works by widening and relaxing the blood vessels, thereby lowering blood pressure.


    The notification released by NPPA added that the manufacturer may add goods and services tax(GST) only if they have paid actually or it is payable to the Government on the retail price as mentioned.










































































































































































































    Sl.

    No.
    Name of the Formulation /

    Brand Name
    StrengthUnitManufacturer & Marketing CompanyRetail Price

    (Rs.)
    (1) (2)(3)(4)(5)(6)
    1.Escitalopram + Clonazepam Tablet (Andefre- LS)Each film coated tablet contains: Escitalopram Oxalate IP eq. to Escitalopram 5mg,

    Clonazepam IP 0.25mg


    1 Tablet
    M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals Pvt.

    Ltd.
    5.88
    2.Paracetamol + Aceclofenac

    Tablet
    Each uncoated tablet contains: Paracetamol IP 325mg,

    Aceclofenac IP 100mg.
    1 TabletM/s Caplet India Private Limited3.35
    3.Misoprostol TabletEach uncoated tablets contains: Misoprostol 25mcg1 TabletM/s Acme Formulation Pvt. Ltd. / M/s Zydus

    Healthcare Limited
    4.37
    4.Mefenamic Acid + Paracetamol TabletEach uncoated tablets contains: Mefenamic Acid IP 500mg, Paracetamol IP 325mg1 TabletM/s Akums Drugs & Pharmaceuticals Ltd. / M/s Abbott Healthcare

    Pvt. Ltd.
    2.76
    5.Trastuzumab InjectionEach Lyophilized Vial contains: Trastuzumab 150mg1 VialM/s Cadila Healthcare Limited / M/s Glenmark

    Pharmaceuticals Limited
    18400.89
    6.Cilnidipine + Telmisartan + Chlorthalidone

    Tablet
    Each film coated tablet contains: Cilnidipine IP 10mg, Telmisartan IP 40mg

    Chlorthalidone IP 6.25mg


    1 Tablet
    M/s Windlas Biotech Pvt. Ltd. /M/s Emcure Pharmaceuticals

    Limited
    10.43
    7.Metformin + Gliclazide TabletEach uncoated bilayered tablet contains:

    Metformin Hydrochloride IP 500mg (in extended release


    1 Tablet
    M/s Anphar Organics Pvt. Ltd. / M/s Lupin Limited6.31
    form)

    Gliclazide IP 80mg (as modified release form)
    8.Metformin + Gliclazide TabletEach uncoated bilayered tablet contains:

    Metformin Hydrochloride IP 500mg (in extended release form)

    Gliclazide IP 60mg (as modified release form)




    1 Tablet
    M/s Anphar Organics Pvt. Ltd. / M/s Lupin Limited8.64
    9.Telmisartan + Metoprolol Tablet (TELMELIFE – M25)Each film coated bilayered tablet contains: Telmisartan IP 40mg, Metoprolol Succinate IP 23.75mg eq. to Metoprolol

    Tartrate (as extended release form) 25mg




    1 Tablet
    M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals (P) Ltd.9.43
    10.Telmisartan + Metoprolol Tablet (TELMELIFE – M50)Each film coated bilayered tablet contains: Telmisartan IP 40mg,

    Metoprolol Succinate IP 47.5mg eq. to Metoprolol Tartrate (as

    extended release form) 50mg




    1 Tablet
    M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Neomac Pharmaceuticals (P) Ltd.11.72
    11.Propranolol + Flunarizine CapsuleEach hard gelatine capsule contains:

    Propranolol Hydrochloride IP 40mg (as SR pellets), Flunarizine Dihydrochloride BP

    eq. to Flunarizine 5mg (as pellets)




    1 Capsule




    M/s Innova Captab Ltd.

    / M/s Cipla Limited
    6.72
    12.Propranolol + Flunarizine CapsuleEach hard gelatine capsule contains:

    Propranolol Hydrochloride IP 40mg (as SR pellets), Flunarizine Dihydrochloride BP eq. to Flunarizine 10mg (as

    pellets)




    1 Capsule




    M/s Innova Captab Ltd.

    / M/s Cipla Limited
    9.20
    13.Levonorgestrel TabletEach uncoated tablet contains: Levonorgestrel IP 1.5mg

    1 Tablet
    M/s Mylan Laboratories Limited / M/s Mylan Pharmaceutical Private

    Limited
    92.80
    14.Formoterol + Budesonide Respirator suspension

    (Budetrol 0.5)
    Each ml respule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 20mcg,

    Budesonide IP 0.5mg


    Each 2 ML Pack
    M/s Axa Parenterals Ltd. / M/s Macleods Pharmaceutical Limited36.04
    15.Formoterol + Budesonide Respirator suspension

    (Budetrol 1)
    Each ml respule contains: Formoterol Fumarate Dihydrate IP eq. to Formoterol Fumarate 20mcg,

    Budesonide IP 1mg


    Each 2 ML Pack
    M/s Axa Parenterals Ltd. / M/s Macleods Pharmaceutical Limited42.12
    16.Metformin + Glimepiride Tablet (Geminor 0.5)Each uncoated bilayered tablet contains:

    Metformin Hydrochloride IP 500mg, (as Prolonged release form)

    Glimepiride IP 0.5mg




    1 Tablet


    M/s Macleods Pharmaceutical Limited
    3.57
    17.Clobazam SuspensionEach ml suspension contains: Clobazam IP 2.5mg

    1 ML
    M/s Intas Pharmaceutical

    Limited
    2.54
    18.Diclofenac + Chlorzoxazone

    Tablet (MYOSPAS-F )
    Each film coated tablet contains: Diclofenac Potassium BP 50mg Chlorzoxazone USP 500mg

    1 Tablet
    M/s G. S. Pharmbutor Pvt. Ltd. /M/s Win- Medicare Pvt. Ltd.9.28
    19.Clonazepam Orally disintegrating

    Strips (Melzap ODS 0.5)


    Each Orally disintegrating Strips contains:

    Clonazepam IP 0.5mg


    1 Orally disintegrating Strip


    M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd.
    5.33
    20.Clonazepam Orally disintegrating Strips (Melzap

    ODS 1)


    Each Orally disintegrating Strips contains:

    Clonazepam IP 1mg


    1 Orally disintegrating Strip


    M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd.
    7.25
    21.Clonazepam Orally disintegrating

    Strips (Melzap ODS 2)


    Each Orally disintegrating Strips contains:

    Clonazepam IP 2mg


    1 Orally disintegrating Strip


    M/s ZIM Laboratories Limited / M/s Alkem Laboratories Ltd.
    13.05

    Also Read: Launching product without Approval: DOP rejects Biocon Plea against NPPA action
    21 drug formulationsBP drugCiplaDPCODrugs Price Control OrderEmcureformulationsindian pharma newslatest pharma newsLupinMacleodsMylanNational Pharmaceutical Pricing AuthorityNPPANPPA price Fixationpainkillerpharma newspharma news in indiaprice fixationzydus

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Meghna A Singhania
    Meghna A Singhania

      Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok